Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02943460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02943460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2016
Completion date
May 18, 2020
Enrollment
52 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis